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Abstract
The novelty and uncertainty associated with COVID-19 has created challenges for politicians, 
citizens, and healthcare providers, leaving no one unaffected. As members of the front line of 
defense, providers in Emergency Departments (EDs) face the momentous challenge of effec-
tively identifying and treating patients with COVID-19, working with experts in Infectious Dis-
ease, Internal Medicine, Critical Care, Public Health, and others. We must coordinate these ef-
forts while also protecting staff, implementing strategies to reduce transmission, and managing 
ED patients with conditions unrelated to COVID-19. Striving to maintain a grasp of the rapidly 
accumulating publications in medical journals and the media, we provide this brief article as a 
pragmatic summary of the challenges facing the ED. 
The new coronavirus SARS-CoV-2 causes COVID-19, a worldwide pandemic as of March 
11, 2020, according to the World Health Organization. The infection has demanded un-
precedented changes within the healthcare systems of all countries. [1] Leaders obtain 
frequent data updates on adequate treatment methods, advice for hospital protocols, 
new statistical models, and physical distancing/government mandated guidelines. The 
novelty and uncertainty associated with SARS-CoV-2 has created challenges for politi-
cians, citizens, and healthcare providers, leaving no one unaffected. As members of the 
front line of defense, providers in Emergency Departments (EDs) face the momentous 
challenge of effectively identifying and treating patients with COVID-19, working with 
experts in Infectious Disease, Internal Medicine, Critical Care, Public Health, and oth-
ers. We must coordinate these efforts while also protecting staff, implementing strat-
egies to reduce transmission, and managing ED patients with conditions unrelated to 
COVID-19. Striving to maintain a grasp of the rapidly accumulating publications in med-
ical journals and the media, we provide this brief article as a pragmatic summary of the 
challenges facing the ED.
The response to the COVID-19 wave of infection in a community begins with planning. 
Emergency providers must work with hospital leadership, community officials / health 
departments, laboratory personnel, emergency ancillary staff, respiratory therapists, 
pharmacists, and the consulting physicians who will help manage patients. Most cities 
fortunately benefitted from some warning of the infection before experiencing local 
surges that would overwhelm capacity. However, hospitals and EDs have experienced 
significant burdens in the management and mitigation of COVID-19. The preparation 
phase involves procurement of personal protective equipment (PPE), modification of 
work schedules, coordination of disaster preparedness and testing capacity, COVID-19 
units for inpatients, pharmacologic and ventilatory treatment consensus, triage mod-
ifications such as outdoor tents, and operational challenges related to caring for both 
COVID-19 and non-COVID-19 patients (trauma, stroke, etc.). Education and updates 
have also proven difficult, requiring daily communication to frontline staff, while main-
taining standards consistent with the changing information and data from places further 
along in outbreaks.
In addition, most hospitals were forced to cancel elective procedures in order to prepare 
for the possible surge of patients with COVID-19. This has resulted in significant finan-
cial burdens for hospitals and universities, with large amounts of lost revenue and re-
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sultant employee furloughs and job losses. While hospitals in major cities like New York City have been over-run with 
patients, many across the country are facing a significant decline in volumes and will likely require financial assistance 
to stay afloat.
Many factors will determine the strain of a COVID-19 wave that reaches each community: temperature and humidity, 
baseline population characteristics, per capita healthcare resources, nonpharmaceutical measures to decrease spread, 
and more. [2-4] The lack of guidelines and therapies during these unparalleled times have been especially challenging. 
[5] Emergency departments have had to quickly adapt and utilize procedures to triage and identify possible COVID-19 
patients effectively. [6] Once patients with COVID-19 begin presenting to EDs within a community, ED leaders must 
implement plans for prehospital care (Emergency Medical Services (EMS) and air transport), triage and isolation of 
contagious patients, continuous care, and disposition to home or inpatient wards. Prehospital dispatchers should in-
quire about infectious symptoms when responding to calls. EMS workers must have proper PPE (contact and respira-
tory isolation) and protocols to decontaminate air and ground ambulances. Prehospital services should avoid aerosoliz-
ing procedures and should observe airborne precautions for patients who are critically ill or require intubation en route 
to the hospital. 
Patients suspected of having COVID-19 who arrive by private vehicle or EMS should be placed directly in isolation 
treatment rooms. Staff (wearing PPE) should place a surgical mask on these patients and attempt to maintain 6 ft dis-
tance when possible. Patients who may need intubation or other aerosolizing procedure, and those who are critically 
ill, should be placed in negative pressure isolation rooms. ED staff should at minimum wear surgical masks, gowns, 
gloves, eye protection, frequently wash hands or use hand sanitizer; and learn proper doffing techniques. When per-
forming (or present for) aerosolizing procedures, ED staff should use an N95 respirator or PAPR. 
Frontline workers in the ED must become familiar with the epidemiology and clinical presentation of patients with 
COVID-19. These features differ based on geographic location, baseline health, age, etc. Data continue to accumulate 
from many countries describing the presenting features of COVID-19 patients, with great variability in cough, fever, 
and gastrointestinal symptoms. Pediatric patients appear to resist infection with SARS-CoV-2, and when infected will 
generally have mild or subclinical symptoms, though can progress to severe status or death. [7] Most adult patients will 
have mild symptoms, though depending on age groups, as many as 20% may require hospitalization, and as many as 5% 
ICU level care. The average age of patients ranges in the 50s, and males are more likely to have COVID-19 and to die 
from it. The overall case fatality rate varies greatly by country/region, but likely ranges from 0.5% to 5%. [8-11] Health-
care workers seem particularly affected depending on the country and resources, and the elderly (particularly nursing 
home residents) clearly experience the greatest mortality rate. 
The incubation period may last as long as 14 days, and patients may be contagious but asymptomatic for 5 days. [12] This 
asymptomatic carrier concern raises important issues for ED workers: All patients presenting to the ED during periods 
of high prevalence should be considered potential COVID-19 patients. [13] COVID-19 can present as focal neurologic 
deficits (and stroke), altered mental status, lethargy, headache, malaise, myalgias, gastroenteritis, venous or arterial 
thrombosis, and other masquerading presentations. [14-21] However, COVID-19 usually presents similarly to other vi-
ral upper respiratory illnesses: rhinorrhea, cough, sneezing, sore throat, congestion. [14] Patients will usually have at 
least a history of fever, if not fever while in the ED. Patients often have cough or dyspnea, though some with rapid respi-
ratory rate do not actually complaint of dyspnea. Some patients will recall high risk contact with infected individuals, 
but even early on, not all patients with COVID-19 have known contact with infected individuals.
Emergency physicians perform assessment of the ABCs (airway, breathing, circulation) immediately on all patients. 
We call attention to commentary from ED Critical Care experts on the avoidance of ‘knee jerk’ intubation in hypoxic 
COVID-19 patients, as prone positioning and high flow nasal cannula can ameliorate even severe respiratory distress. 
[22] Patients suspected of having COVID-19 who might require intubation should be isolated in a negative pressure 
room. Crash intubation should be avoided if possible. The most experienced physician should perform the intubation 
with video (not direct) laryngoscopy, and should wear double gown, double gloves and either PAPR or face shield, eye 
protection, and surgical mask over their N95 respirator. Some hospitals have initiated an intubation team to perform 
all intubations. [23] Preoxygenation should be optimized without aerosolizing procedures, with rare use of CPAP and 
BiPAP. The ventilator circuit should have a viral filter, and the room should have a HEPA filter. Ventilator management 
should avoid pulmonary trauma and follow ARDS guidelines as closely as possible. [24] 
With no firm definitions established and widely accepted, COVID-19 has been divided into illness trajectories: mild 
upper respiratory disease, moderate lower respiratory involvement (pneumonia), and severe disease including an AR-
DS-like picture and critical status. [14] The ED evaluation and workup should vary based on initial impression of illness 
severity. Patients with mild URI symptoms, especially if in good health, likely do not require laboratory testing. The 
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use of screening for COVID-19 by nasal swab will differ based on local resources, but patients with mild symptoms 
presumed to have the disease should quarantine at home for 14 days or until asymptomatic for at least 72 hours. Chest 
imaging with ultrasound and/or radiograph can be considered in mild cases, though likely will not change manage-
ment. Most patients in the mild category should be discharged from the ED. The decision to consult infectious disease 
will vary by local practices. 
Patients with underlying disease or a more severe clinical presentation will benefit from workup, including SARS-
CoV-2 testing, laboratory tests, and imaging. The RT-PCR assay for the virus remains standard of care, though newer 
methods continue development, and antibody testing will likely become more prevalent. PCR testing has a concerning 
amount of false negatives (sensitivity 66-80%), and therefore should be repeated on patients in whom suspicion re-
mains high. [14] Positive testing for other respiratory infections does not rule out COVID-19 disease. [25] Recent data 
does suggest that normal chest X-ray lowers the probability of COVID-19 illness. [26] Used early in the pandemic as a 
screening test, chest CT may add little to chest X-Ray and exposes the patient to large dose of radiation with minimal 
benefit. [27] Point of care lung ultrasound can show B lines, consolidations, and a thickened pleural line. [14] The com-
plete blood count may show lymphopenia, thrombocytopenia, and anemia, though some patients will have elevated he-
moglobin. Other laboratory findings of significance include elevated creatine kinase and creatinine, elevated d-dimer 
and lactate dehydrogenase, ferritin, C-reactive protein, troponin, brain natriuretic peptide. 
Researchers have attempted to identify features of illness on initial presentation that could predict clinical deteriora-
tion in the coming days (usually 3 days post admission). Factors that have shown this association are myalgias, hypox-
emia, AST and ALT elevation, high hemoglobin, advanced age and comorbidities. [28-32] Research has shown several 
factors predicting need for inpatient care and subsequent mortality: old age, cancer, immunocompromised state, diabe-
tes, smoking, hypertension, cardiovascular diseases, metabolic disease/obesity, chronic obstructive pulmonary disease 
(COPD). [14] 
Medical literature on treatment for COVID-19 is in constant flux, with aggressive research in progress for antiviral 
drugs, antibody approaches, and the search for a vaccine. Supportive care remains the primary treatment for moderate 
and severe patients. Of note, the early intubation approach has come under intense scrutiny, and we believe intubation 
should be avoided as long as possible. Early prone positioning and high flow nasal cannula appear to be very effective 
even in moderately hypoxemic patients. [22] Providers should show care in IV fluid resuscitation, and most patients 
are not volume depleted on presentation, and aggressive fluid resuscitation likely worsens pulmonary physiology. As 
data accumulates, more coherent guidelines on pharmacologic management will come. Lopinavir-ritonavir appears to 
offer no benefit. [33] Hydroxychloroquine and chloroquine could serve as prophylaxis more than treatment, and should 
likely not be combined with azithromycin. [34] Remdesivir may not ultimately provide a significant mortality benefit, 
though trials continue. [35] Patients with secondary bacterial infection should receive antibiotics. For very ill patients, 
the IL-6 inhibitor tocilizumab has shown some benefit. [36] Treatment in the Emergency Department will be largely 
supportive, and the most crucial decision could be the careful delay of endotracheal intubation. 
As above, patients with mild URI symptoms should be discharged home in quarantine, with firm instructions on rea-
sons to return to the ED. Patients with pneumonia and more severe disease could require admission, based on vital 
signs, laboratory findings, and presence of pre-existing conditions. Testing should occur in compliance with resources 
and in coordination with the local health department. All patients should maintain social distancing and avoid interac-
tion with vulnerable populations. 
Even when following evidence-based practice, EDs will have inevitable challenges related to operation during a pan-
demic. Should all patients coming to the ED receive a mask, for patient and staff protection? We assert that all infec-
tious patients should don a surgical mask on arrival. Should any patients remain in the waiting area, or should triage 
be performed at the bedside? Should we allow ‘homemade’ PPE use? Should front-line workers be penalized for not 
working due to fear for their own health? Should those who come to work with fever or other infectious symptoms be 
sent home, even in the midst of personnel shortage? When should we consult the Infectious Disease service? Which 
COVID suspicious patients should be tested? How should we approach the trainee workforce? In the US currently, res-
idents maintain their schedules, yet medical students as of May 11, 2020 have not returned to clinical duties. Research 
and educational limitations affect academic emergency physicians. 
We propose discussion on these concerns, but provide no definitive answers. As a Level 1 Trauma Center and compre-
hensive stroke center, the University of Louisville ED has unique challenges. Our major resuscitation room has four 
bays for patient care in a large open area, causing concerns with isolation and negative pressure. We recommend thor-
ough screening of all trauma, stroke and other patients prior to placement in an ED room, to prevent contamination 
of staff and our critical resuscitation bay. Additionally, we concur with publications that have highlighted the atypical 
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presentations of COVID-19 disease, having cared for stroke patients, blunt and penetrating trauma patients who were 
found to have COVID-19 on admission testing. Specifically, many stroke and trauma patients with positive COVID-19 
testing had no signs or symptoms of infection at the time of ED presentation and care. 
While improvements in testing continue, availability and accuracy remain tenuous, and the US has not been aggressive 
with contact tracing. Screening will enhance clinical care within the ED but also help leaders make critical decisions on 
lifting of isolation guidelines as we aim to return to ‘normal’. We praise efforts in determining strategies to help popula-
tions uniquely affected by COVID-19, including persons from low socioeconomic backgrounds, racial minority groups, 
geriatric patients, and individuals with substance use disorder. We also applaud efforts in researching ways to deliv-
er healthcare in different patient-provider interaction settings during pandemics such as in the area of telemedicine. 
Furthermore, we agree with Duanmu et al that developing robust databases on COVID-19 patients presenting to the 
ER will allow us to effectively make better data-informed decisions [37]. Publications on COVID-19 should be founded 
in scientific inquiry, not politics, and should not be locked behind paywalls. Establishing research investigations and 
collaborative agreements in a systematic way will allow us to reduce duplicative efforts and optimize scientific break-
throughs. We also must consider the potential large wave of infections that will come in the fall of 2020, if the summer 
does in fact reduce infection transmission and incidence. Finally, we must recognize that everyone involved in caring 
for COVID-19 patients is impacted to varying degrees. Let us remain connected, share our experiences, and learn from 
one another.
Acknowledgments
The authors would like to acknowledge Jessica Petrey, the UofL librarian, for her assistance in obtaining and organiz-
ing up to date references.
References
1. Rismanbaf A. Potential Treatments for COVID-19; a Narrative Literature Review. Arch Acad Emerg Med. 2020 Mar 
21;8(1):e29.
2. Ferguson NM, Laydon D, Nedjati-Gilani G, Imai N, Ainslie K, Baguelin M, et al. Impact of non-pharmaceutical in-
terventions (NPIs) to reduce COVID-19 mortality and healthcare demand. Imperial College COVID-19 Response 
Team. March 16 2020. https://www.imperial.ac.uk/mrc-global-infectious-disease-analysis/covid-19/report-9-im-
pact-of-npis-on-covid-19/
3. Cheng VC, Wong SC, Chen JH, Yip CC, Chuang VW, Tsang OT, et al. Escalating infection control response to the 
rapidly evolving epidemiology of the coronavirus disease 2019 (COVID-19) due to SARS-CoV-2 in Hong Kong. In-
fect Control Hosp Epidemiol. 2020 May;41(5):493–8. https://doi.org/10.1017/ice.2020.58 PMID:32131908
4. Singer AJ, Morley EJ, Henry MC. Staying Ahead of the Wave. N Engl J Med. 2020 Apr;382(18):e44. https://doi.
org/10.1056/NEJMc2009409 PMID:32283005
5. Mehta N, Mazer-Amirshahi M, Alkindi N, Pourmand A. Pharmacotherapy in COVID-19; A narrative review for emer-
gency providers. Am J Emerg Med. 2020 Apr;S0735-6757(20)30263-1. https://doi.org/10.1016/j.ajem.2020.04.035 
PMID:32336586
6. Hunt M, Koziatek C. A Case of COVID-19 Pneumonia in a Young Male with Full Body Rash as a Presenting Symp-
tom. Clin Pract Cases Emerg Med. 2020 Mar;4(2). https://doi.org/10.5811/cpcem.2020.3.47349 PMID:32282312
7. Ludvigsson JF. Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults. 
Acta Paediatr. 2020 Jun;109(6):1088–95. https://doi.org/10.1111/apa.15270 PMID:32202343
8. Lai CC, Wang CY, Wang YH, Hsueh SC, Ko WC, Hsueh PR. Global epidemiology of coronavirus disease 2019 
(COVID-19): disease incidence, daily cumulative index, mortality, and their association with country healthcare 
resources and economic status. Int J Antimicrob Agents. 2020 Apr;55(4):105946. https://doi.org/10.1016/j.ijantim-
icag.2020.105946 PMID:32199877
9. Wu YC, Chen CS, Chan YJ. The outbreak of COVID-19: an overview. J Chin Med Assoc. 2020 Mar;83(3):217–20. 
https://doi.org/10.1097/JCMA.0000000000000270 PMID:32134861
10. Yi Y, Lagniton PN, Ye S, Li E, Xu RH. COVID-19: what has been learned and to be learned about the novel coronavi-
rus disease. Int J Biol Sci. 2020 Mar;16(10):1753–66. https://doi.org/10.7150/ijbs.45134 PMID:32226295
11. Petrosillo N, Viceconte G, Ergonul O, Ippolito G, Petersen E. COVID-19, SARS and MERS: are they closely related? 
Clin Microbiol Infect. 2020 Mar;S1198-743X(20)30171-3. https://doi.org/10.1016/j.cmi.2020.03.026 PMID:32234451
12. Arons MM, Hatfield KM, Reddy SC, Kimball A, James A, Jacobs JR, et al. Presymptomatic SARS-CoV-2 Infections 
and Transmission in a Skilled Nursing Facility. N Engl J Med. 2020 Apr;NEJMoa2008457. https://doi.org/10.1056/
NEJMoa2008457 PMID:32329971
13. Wee LE, Fua TP, Chua YY, Ho AFW, Sim XYJ, Conceicao EP, Venkatachalam I, Tan KB, Tan BH. Containing 
COVID-19 in the Emergency Department: The Role of Improved Case Detection and Segregation of Suspect Cases. 
ULJRI | https://doi.org/10.18297/jri/vol4/iss1/13 5
ULJRI Emergency Medicine in the Time of COVID
Acad Emerg Med. 2020  May;27(5):379-387. doi: 10.1111/acem.13984. Epub 2020 May 11. PMID: 32281231. 
14. Chavez S, Long B, Koyfman A, Liang SY. Coronavirus Disease (COVID-19): A primer for emergency physicians. Am 
J Emerg Med. 2020 Mar;S0735-6757(20)30178-9. https://doi.org/10.1016/j.ajem.2020.03.036 PMID:32265065
15. Li LQ, Huang T, Wang YQ, Wang ZP, Liang Y, Huang TB, et al. COVID-19 patients’ clinical characteristics, discharge 
rate, and fatality rate of meta-analysis. J Med Virol. 2020 Mar;92(6):577–83. https://doi.org/10.1002/jmv.25757 
PMID:32162702
16. Lechien JR, Chiesa-Estomba CM, Place S, Van Laethem Y, Cabaraux P, Mat Q, et al.; COVID-19 Task Force of 
YO-IFOS. Clinical and Epidemiological Characteristics of 1,420 European Patients with mild-to-moderate Corona-
virus Disease 2019. J Intern Med. 2020 Apr;joim.13089. https://doi.org/10.1111/joim.13089 PMID:32352202
17. Pascarella G, Strumia A, Piliego C, Bruno F, Del Buono R, Costa F, et al. COVID-19 diagnosis and management: a 
comprehensive review. J Intern Med. 2020 Apr;joim.13091. https://doi.org/10.1111/joim.13091 PMID:32348588
18. Das G, Mukherjee N, Ghosh S. Neurological Insights of COVID-19 Pandemic. ACS Chem Neurosci. 2020 
May;11(9):1206–9. https://doi.org/10.1021/acschemneuro.0c00201 PMID:32320211
19. Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, Chang J, Hong C, Zhou Y, Wang D, Miao X. Neurologic manifestations 
of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA neurology. 2020 Apr 10.
20. Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E, et al. COVID-19 and Thrombotic or Throm-
boembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up. J Am Coll Cardiol. 2020 
Apr;S0735-1097(20)35008-7. https://doi.org/10.1016/j.jacc.2020.04.031 PMID:32311448
21. Carod-Artal FJ. Neurological complications of coronavirus and COVID-19. Rev Neurol. 2020 May;70(9):311–22. 
PMID:32329044
22. Caputo ND, Strayer RJ, Levitan R. Early Self-Proning in Awake, Non-intubated Patients in the Emergency Depart-
ment: A Single ED’s Experience During the COVID-19 Pandemic. Acad Emerg Med. 2020 May;27(5):375–8. https://
doi.org/10.1111/acem.13994 PMID:32320506
23. Luo M, Cao S, Wei L, Tang R, Hong S, Liu R, et al. Precautions for Intubating Patients with COVID-19. Anesthesiol-
ogy. 2020 Mar;132(6):1616–8. https://doi.org/10.1097/ALN.0000000000003288 PMID:32195703
24. Poston JT, Patel BK, Davis AM. Management of Critically Ill AdultsWith COVID-19. JAMAClinical Guidelines Syn-
opsis. 2020.
25. Kim D, Quinn J, Pinsky B, Shah NH, Brown I. Rates of Co-infection Between SARS-CoV-2 and Other Respiratory 
Pathogens. JAMA. 2020 Apr. https://doi.org/10.1001/jama.2020.6266 PMID:32293646
26. Cummings MJ, Baldwin MR, Abrams D, Jacobson SD, Meyer BJ, Balough EM, et al. Epidemiology, clinical course, 
and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. medRxiv. 
2020:2020.04.15.20067157.
27. Hope MD, Raptis CA, Henry TS. Chest Computed Tomography for Detection of Coronavirus Disease 2019 
(COVID-19): Don’t Rush the Science. Ann Intern Med. 2020.
28. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients 
with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020 Mar;395(10229):1054–62. https://doi.
org/10.1016/S0140-6736(20)30566-3 PMID:32171076
29. Zhou M, Zhang X, Qu J. Coronavirus disease 2019 (COVID-19): a clinical update. Front Med. 2020 Apr;14(2):126–
35. https://doi.org/10.1007/s11684-020-0767-8 PMID:32240462
30. Terpos E, Ntanasis-Stathopoulos I, Elalamy I, Kastritis E, Sergentanis TN, Politou M, et al. Hematological findings 
and complications of COVID-19. Am J Hematol. 2020 Apr. https://doi.org/10.1002/ajh.25829 PMID:32282949
31. Ji D, Zhang D, Xu J, Chen Z, Yang T, Zhao P, et al. Prediction for Progression Risk in Patients with COVID-19 Pneu-
monia: the CALL Score. Clin Infect Dis. 2020 Apr;ciaa414. https://doi.org/10.1093/cid/ciaa414 PMID:32271369
32. Cai Q, Huang D, Yu H, Zhu Z, Xia Z, Su Y, Li Z, Zhou G, Gou J, Qu J, Sun Y, Liu Y, He Q, Chen J, Liu L, Xu L. COVID-19: 
Abnormal liver function tests. J Hepatol. 2020 Apr 13:S0168-8278(20)30218-X. doi: 10.1016/j.jhep.2020.04.006. 
Epub ahead of print. 
33. Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe 
Covid-19. N Engl J Med. 2020 May;382(19):1787–99. https://doi.org/10.1056/NEJMoa2001282 PMID:32187464
34. Magagnoli J, Narendran S, Pereira F, Cummings T, Hardin JW, Sutton SS, Ambati J. Outcomes of hydroxychloro-
quine usage in United States veterans hospitalized with Covid-19. medrxiv. 2020 Jan 1.
35. Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, et al. Remdesivir in adults with severe COVID-19: a randomised, dou-
ble-blind, placebo-controlled, multicentre trial. Lancet. 2020. https://doi.org/10.1016/S0140-6736(20)31022-9. In 
press.
36. Xu X, Han M, Li T, Sun W, Wang D, Fu B, Zhou Y, Zheng X, Yang Y, Li X, Zhang X, Pan A, Wei H. Effective treatment 
of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci U S A. 2020 Apr 29:202005615. doi: 10.1073/
pnas.2005615117. Epub ahead of print. 
37. Duanmu Y, Brown IP, Gibb WR, Singh J, Matheson LW, Blomkalns AL, Govindarajan P. Characteristics of Emer-
gency Department Patients With COVID-19 at a Single Site in Northern California: Clinical Observations and Pub-
lic Health Implications. Acad Emerg Med. 2020 Apr 28. doi: 10.1111/acem.14003. Epub ahead of print.
